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Abstract
A 29-year-old woman with schizophrenia introduced for application of repetitive transcranial magnetic stimulation for refractory
visual hallucinations. Following inhibitory rTMS on visual cortex she reported significant reduction in severity and simplification
of complexity of hallucinations, which lasted for three months. rTMS can be considered as a possibly potent treatment for visual
hallucinations.
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1. Introduction
Visual hallucinations influence the lives of millions of
people affected by different disorders. Schizophrenia and
other different types of psychosis are the most frequent
disorders, which may be accompanied by visual hallucina-
tions (1). Visual hallucinations have been reported in 16% to
72% of patients with schizophrenia or schizoaffective dis-
orders and it is one of the diagnostic criteria of schizophre-
nia (2-4) and its presence is related to the severity of illness
(5).
Nowadays ant dopaminergic antipsychotics and
serotonin-dopamine antagonists are the only therapeutic
choices and recently anti-acetyl cholinesterase agents have
been suggested (6). Despite all these treatments, patients
may have refractory hallucinations. Transcranial magnetic
stimulation (rTMS) is a technique using magnetic field
for stimulation of brain. In July 2011, the FDA introduced
rTMS system as Class II (special controls) in the federal
register by the phrase of:” in order to provide a reasonable
assurance of safety and effectiveness of these devices” (7).
rTMS could be a promising therapeutic method for visual
hallucinations, due to the theories which suggest cortical
hyperactivity as a probable mechanism for unreal visual
sensations (8-10).
We could find three case reports reporting the effects
of rTMS on visual hallucinations. Firstly, a 52-year-old pa-
tient who lost his vision partially follows a myocardial
infarction. His hallucinations were multi-colored round
lights, humanoid corps and faces. Merabet et al. (11) at Har-
vard medical school reported immediate remission last-
ing for a week following stimulating the visual cortex (2
cm above the patient’s inion, 1 Hz, 10 minutes), which had
not been induced by sham stimuli given previously. The
researchers suggested that probably the reduction of in-
creased cortical excitability is the mechanism of respon-
siveness.
The second case was a 32-year-old patient with refrac-
tory paranoid schizophrenia affected by complex halluci-
nations involving auditory, visual and olfactory systems.
Jardri et al. (8) in France conducted a functional neu-
roimaging with electrical source reconstruction and con-
sidered Occipito-Temporal Sulcus as the target of stimula-
tion. In 2009, the team reported that 10 sessions of low fre-
quency (1 Hz), suppressed hallucinations significantly leav-
ing minimum residues including tinnitus and phosphine.
The third case was a 50-year-old woman experienc-
ing visual sensations including changing colors and lights
since loss of her vision bilaterally, suggestive of the Charles
Bonnet syndrome. Functional MRI showed hyperactivity in
extra-striate visual area V5/MT and the fusiform gyrus (V4)
related to visual sensations, where Meppelink et al. (12) se-
lected them as target of rTMS. The premier sham stimula-
tion on V5 could not make any change, but later session of
real rTMS by frequency of 1 Hz at V5/MT and V1 led to almost
complete suppression of a part of hallucinations for two
days. Three extra sessions of stimulation after two months
could cause infinitesimal relief.
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2. Case Presentation
The patient was a 29-year-old woman who had received
psychiatric treatments since the age of 19, following talk-
ing to herself, grandiosity and persecutory delusions, irri-
tability and aggressiveness. The diagnosis of schizophre-
nia confirmed by SCID-I interview based of DSM-IV-TR,
when the visual hallucinations commenced without symp-
toms of any mood disorder. Electroencephalography and
brain magnetic resonance imaging did not reveal any ab-
normality, as well as laboratory results. The content of hal-
lucinations was strange persons with threatening facial ex-
pressions.
At the time of introduction to neurotherapy unit of
Rasoul-Akram hospital in December 2013, she took 400 mil-
ligram of clozapine per day, but she still had refractory vi-
sual hallucinations. She had insight that these persons are
not real, but they still made her anxious. She had experi-
enced a wide variety of classical and atypical agents with
full therapeutic dosage and for enough duration that just
resulted in few periods of transient partial remission. The
team decided to perform inhibitory stimulation on her
brain hoping to diminish hallucinations.
The patient received 12 sessions of rTMS, 5 times per
week (1 Hz frequency, for 20 minutes, 100% of the motor
threshold, Magventure; Mag Machine pro ×100) on O2,
continuing the medications as before. Before the fifth ses-
sion, she reported decrease in the frequency of hallucina-
tions as low as 5, considering 10 for description of the pre-
treatment situation using analog visual scale. At the end
of therapeutic course, she reported that the frequency and
severity limited to 2.5. She described those persons ap-
pear less than before and less frightening. Her mother and
her psychiatrist also confirmed improvement in her symp-
toms, mood and irritability. She did not report any imme-
diate or delayed adverse effect. At follow-up interview af-
ter three months, she was still satisfied with the outcomes
and hallucinations were limited to rare appearances of hu-
manoid features.
3. Discussion
This result supports our hypothesis about effectiveness
of rTMS in treatment of visual hallucinations and is com-
patible with the cortical hyperexcitability theory about its
pathogenesis. As it can be concluded of the Dr Jardri’s case
report, functional neuroimaging may be beneficial in lo-
calizing a specific target for stimulation and may prevent
wasting time and cost on targets, which are less possible to
be involved in the pathogenesis (8). Although this combi-
nation seems to be efficacious, it may not be possible every-
where. Existing evidence suggests in the absence of func-
tional imaging that Occipital area is a promising target, be-
cause of probable role of the occipital cortex in the chain of
pathogenesis of visual hallucination (13).
rTMS can be investigated as a method for the treatment
of visual hallucinations, especially for refractory types. We
suggest basic studies by functional imaging on visual hal-
lucination (both in refractory and responsive cases). Prior-
ity of basic localizing studies may prevent bias in the re-
sults of studies to ineffectiveness due to targeting irrele-
vant points, and leads to acceleration in achievement of a
consensus on efficiency of rTMS on visual hallucinations.
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